Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,736 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Administration first Clear all

Conditions: Allergic Conjunctivitis
Interventions: Prednisolone Acetate 0.12% (Pred Mild®), FOV1101-00, Prednisolone Acetate 1% (Pred Forte®), Placebo; Drug
Lead sponsor: Fovea Pharmaceuticals SA; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Type 1 Diabetes Mellitus
Interventions: Propranolol 80 Mg Oral Capsule, Extended Release, Placebo oral capsule; Drug
Lead sponsor: Anu Sharma; Other
Eligibility: 21 Years to 59 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Delirium, Delirium, Dementia, Amnestic, Cognitive Disorders, Delayed Emergence From Anesthesia, Cognitive Disorders
Interventions: Ramelteon, Microcrystalline Cellulose, Riboflavin 100 mg; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Gastric Cancer
Interventions: Rilotumumab, Placebo, Epirubicin, Cisplatin, Capecitabine; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 16
States / cities: Tucson, Arizona • Aurora, Colorado • Pueblo, Colorado + 13 more

Conditions: Sickle Cell Anemia, Priapism
Interventions: tadalafil, placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 45 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Dermatomyositis
Interventions: Octagam 10%, Placebo; Drug · Other
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 17
States / cities: Huntington Beach, California • Los Angeles, California • Orange, California + 14 more

Conditions: Alcohol-associated Hepatitis
Interventions: IL-22, Prednisone, Acamprosate, Prednisone placebo, IL-22 (F-652) Placebo, Motivational Interviewing (MI), Motivational Enhancement Therapy (MET), Usual Care; Drug · Behavioral
Lead sponsor: Samer Gawrieh; Other
Eligibility: 18 Years to 70 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: Indianapolis, Indiana • Louisville, Kentucky • Rochester, Minnesota + 3 more

Conditions: End-stage Kidney Disease, Kidney Disease, Chronic, Dialysis, Diabetic, Non-diabetic, Kidney Dysfunction, Kidney Failure, Hemodialysis
Interventions: Empagliflozin, Placebo; Drug · Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Muscle Wasting, Non Small Cell Lung Cancer
Interventions: GTx-024, placebo; Drug
Lead sponsor: GTx; Industry
Eligibility: 30 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 27
States / cities: Birmingham, Alabama • Long Beach, California • Aventura, Florida + 24 more

Conditions: Infertility
Interventions: MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL, MENOPUR powder and solvent for solution for injection, 75 IU, Placebo (for MENOPUR solution for injection in pre-filled pen), Placebo (for MENOPUR powder and solvent for solution for injection); Drug · Other
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 20
States / cities: Tempe, Arizona • San Diego, California • Farmington, Connecticut + 17 more

Conditions: Rheumatoid Arthritis
Interventions: CFZ533, Placebo; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Anniston, Alabama • Miami, Florida • South Miami, Florida + 2 more

Conditions: Pancreatic Cancer
Interventions: Simtuzumab, Gemcitabine, Placebo to match simtuzumab; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 44
States / cities: Birmingham, Alabama • Mobile, Alabama • Alhambra, California + 40 more

Conditions: Alzheimer's Disease
Interventions: Semorinemab, Placebo, [18F]GTP1; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 31
States / cities: Garden Grove, California • Los Alamitos, California • Palo Alto, California + 28 more

Conditions: Pancreatic Cancer
Interventions: ABTL0812, Folfirinox, Placebo; Drug
Lead sponsor: Ability Pharmaceuticals SL; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Los Angeles, California • Westwood, Kansas • Boston, Massachusetts + 1 more

Conditions: Major Depressive Disorder
Interventions: Escitalopram Pill, Placebo, Levomilnacipran Pill; Drug · Other
Lead sponsor: Howard Aizenstein; Other
Eligibility: 60 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Sickle Cell Disease
Interventions: Prasugrel, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 20
States / cities: Oakland, California • Palo Alto, California • Hartford, Connecticut + 16 more

Conditions: Schizophrenia
Interventions: RBP-7000, Placebo, Risperidone; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 32
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Cerritos, California + 25 more

Conditions: Covid19, SARS-CoV Infection, ARDS, ARDS, Human
Interventions: Instilled T3, Placebo Therapy; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Alcohol Dependence, Post-Traumatic Stress Disorder (PTSD)
Interventions: Progesterone, Placebo (for Progesterone); Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 60 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Vertigo, Benign Paroxysmal Positional Vertigo
Interventions: Standard Repositioning, Mechanical Chair Repositioning, Sham Treatment; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Graft Rejection
Interventions: Placebo, C1 Esterase Inhibitor (Human); Biological
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 1 more

Conditions: Cognitive Impairment, RRSO
Interventions: Lisdexamfetamine, Placebo oral capsule; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 35 Years to 58 Years · Female only
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Colorectal Cancer
Interventions: Oxaliplatin 130 mg/m^2, Capecitabine 1000 mg/m^2, Bevacizumab 7.5 mg/kg, Placebo for bevacizumab 7.5 mg/kg, Oxaliplatin 85 mg/m^2, Leucovorin 200 mg/m^2, Fluorouracil 400 mg/m^2, Bevacizumab 5 mg/kg, Placebo for bevacizumab 5 mg/kg; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 2,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 49
States / cities: Berkeley, California • Fountain Valley, California • Fullerton, California + 44 more

Conditions: Type 1 Diabetes Mellitus
Interventions: CTLA-4 Ig, Placebo; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Years to 45 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 9 more

Search by objective public record fields.

Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation

Propranolol in Treating Hypoglycemia Unawareness

Ramelteon in the Prevention of Post-operative Delirium

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia

Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)

Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial

Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD

Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART)

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients

A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients

Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome

Progesterone Effect on Individuals Diagnoses With AD and PTSD.

Efficacy of a Mechanical Chair for Treatment of Benign Paroxysmal Positional Vertigo (BPPV)

A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection

IMProving Executive Function Study

A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus